ArticleMedicine and pharmacy reports2025
Emotional distress and quality of life in high and moderate penetrance germline mutations carriers diagnosed with breast cancer: a preliminary study.
Article in Medicine and pharmacy reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: Genetic testing plays a critical role in breast cancer management by identifying individuals with high or moderate penetrance gene mutations. While clinical implications are well established, less is known about the psychological and quality-of-life impact of different genetic risk levels. This preliminary study aimed to explore whether breast cancer patients with high penetrance mutations experience different levels of distress compared to those with moderate penetrance mutations. Methods: A total of 110 breast cancer patients treated at the Regina Maria Private Health Network in Cluj-Napoca, Romania, were included based on specific eligibility criteria. Participants completed a shortened version of the BREAST-Q questionnaire, focused on core dimensions such as emotional distress, self-concept, appearance, relationships, and financial burden. Descriptive statistics were calculated, and independent t-tests were performed to compare responses between the two genetic risk groups. Results: Patients with high penetrance mutations reported significantly higher distress levels in several domains, including overall emotional distress (p = 0.039), concern for daughters or relatives (p = 0.043), changes in appearance (p = 0.038), and self-concept (p = 0.043). Other factors, such as fear of diagnosis, financial burden, and impact on sexuality, did not show statistically significant differences between groups. Conclusions: This preliminary study suggests that genetic risk classification may influence the psychosocial experience of breast cancer patients, with high penetrance mutation carriers experiencing greater distress in specific areas. These findings highlight the need for personalized psychosocial support based on genetic profiles and warrant further investigation in larger, longitudinal cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.